A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

Inclusion Criteria:

1. Participant must be ≥ 12 years of age at the time of signing the informedconsent/assent

2. Weight ≥ 35 kg

3. Bronchiectasis diagnosed by a physician and confirmed by CT demonstrating abnormalbronchial dilation in ≥ 1 lobe. Note: A historical CT scan within the past 5 yearsis acceptable. If not available, a CT scan should be conducted at screening toconfirm eligibility.

4. Participants who are receiving appropriate standard of care therapy per localguidelines and have a documented history of ≥ 2 moderate exacerbations or ≥ 1 severeexacerbation in the preceding 12 months requiring antibiotics

5. Participants who are clinically stable and free from an exacerbation ofbronchiectasis for 4 weeks prior to randomization

6. Participants with pre- or post-bronchodilator FEV1 ≥ 25% predicted value atscreening.

7. Presence of positive (PCR or culture) PsA in an airway sample at least once in thelast 24 months prior to screening

8. Presence of culture positive PsA in sputum at least within 5 weeks of randomization.Participants who have previously received PsA eradication therapy, as determinedappropriate by their treating provider, but remain colonized with PsA are eligiblefor the study.

9. Capable of giving signed informed consent/assent which includes compliance with therequirements and restrictions listed in the ICF and in this protocol

Exclusion Criteria:

1. Primary lung diagnosis other than bronchiectasis

2. Evidence of active tuberculosis or active nontuberculous mycobacteria being treatedor requiring treatment. Participants currently receiving treatment for active TB ornontuberculous mycobacteria may be considered after completion of an appropriatecourse of therapy

3. Evidence of an active allergic bronchopulmonary aspergillosis being treated orrequiring treatment

4. Need for long term supplemental oxygen. Oxygen use for ambulation and relief ofbreathlessness after exercise is allowed

5. Malignancy, current or within the previous 5 years, except for stable prostatecancer, adequately treated non-invasive basal cell and squamous cell carcinoma ofthe skin and cervical carcinoma in situ treated with apparent success more than oneyear prior to enrolment

6. AIDS or Advanced human immunodeficiency virus disease (CD4 count of < 200 cells/mm3)

7. History of severe adverse reaction associated with a mAb, and/or history of severeallergic reaction (eg, anaphylaxis that required the use of epinephrine/adrenalineor hospitalization), and/or history of immune complex disease (Type IIIhypersensitivity reactions) to monoclonal antibody administration

8. Treatment with long term anti-PsA antibiotics, macrolides, or DPP-1 inhibitors,which are newly initiated within the 3 months prior to screening

9. Chronic immunosuppressive therapy (including prednisolone > 5 mg or equivalent)newly initiated within the last 3 months

10. Receipt of investigational products indicated for the treatment or prevention ofbronchiectasis exacerbations or expected receipt during the study

11. Participants with CF on CFTR modulator therapies which are newly initiated withinthe previous 3 months prior to screening

12. Female participants who are pregnant, lactating, or WOCBP and not using a highlyeffective method of contraception or abstinence from at least 4 weeks prior to studyintervention administration and until at least 6 months after study interventionadministration